Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
- Conditions
- Interventions
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 700
- Registration Number
- NCT05226598
- Locations
- 🇪🇸
Hospital Clinico San Carlos-Oncology Department ( Site 1107), Madrid, Spain
🇨🇳Jilin Cancer Hospital-oncology department ( Site 2603), Changchun, Jilin, China
🇨🇳Zhejiang Cancer Hospital-Oncology ( Site 2612), Hangzhou, Zhejiang, China
Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05209620
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)
- Conditions
- Interventions
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2024-10-11
- Target Recruit Count
- 110
- Registration Number
- NCT05200481
- Locations
- 🇫🇷
CHU d'Angers, Angers, France
🇫🇷CHU Besançon - Hôpital J. MINJOZ, Besançon, France
🇫🇷Hôpital APHP Ambroise Paré, Boulogne, France
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT05198830
- Locations
- 🇺🇸
Robert Wood Johnson University Hospital Somerset, Somerville, New Jersey, United States
🇺🇸Keck Medicine of USC Buena Park, Buena Park, California, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
- Conditions
- Interventions
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Blueprint Medicines Corporation
- Target Recruit Count
- 20
- Registration Number
- NCT05153408
- Locations
- 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-29
- Last Posted Date
- 2023-12-20
- Target Recruit Count
- 28
- Registration Number
- NCT05136846
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸City of Hope, Duarte, California, United States
A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants
- Conditions
- Interventions
- First Posted Date
- 2021-11-29
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 100
- Registration Number
- NCT05136677
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou Universtiy-Oncology department, Zhengzhou, Henan, China
🇨🇳Local Institution - 0012, Ningbo, Zhejiang, China
🇨🇳Beijing Cancer hospital-Thoracic Cancer Department A, Beijing, Beijing, China
Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- Liaoning Tumor Hospital & Institute
- Target Recruit Count
- 45
- Registration Number
- NCT05132985
- Locations
- 🇨🇳
Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
A Phase II Study of Neoadjuvant Sotorasib in Combination with Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer with a KRAS P.G12C Mutation
- Conditions
- Interventions
- First Posted Date
- 2021-11-12
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT05118854
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 500
- Registration Number
- NCT05116462
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.